Rho inhibitor prevents ischemia-reperfusion injury in rat steatotic liver

J Hepatol. 2012 Jan;56(1):146-52. doi: 10.1016/j.jhep.2011.04.029. Epub 2011 Jul 12.

Abstract

Background & aims: Hepatic stellate cells are thought to play a role in modulating intrahepatic vascular resistance based on their capacity to contract via Rho signaling. We investigated the effect of a Rho-kinase inhibitor on ischemia-reperfusion injury in the steatotic liver.

Methods: Steatotic livers, induced by a choline-deficient diet in rats, were subjected to ischemia-reperfusion injury. Hepatic stellate cells isolated from steatotic livers were analyzed for contractility and Rho signaling activity. The portal pressure of the perfused rat liver and the survival rate after ischemia-reperfusion were also investigated.

Results: Hepatic stellate cells from steatotic livers showed increased contractility and upregulation of Rho-kinase 2 compared with those from normal livers. Furthermore, endothelin-1 significantly enhanced the contractility and phosphorylation level of myosin light chain and cofilin in hepatic stellate cells isolated from steatotic livers. A specific Rho-kinase inhibitor, fasudil, significantly suppressed the contractility and decreased the phosphorylation levels of myosin light chain and cofilin. Serum levels of endothelin-1 were markedly increased after IR in rats with steatotic livers, whereas fasudil significantly decreased endothelin-1 serum levels. Rats with steatotic livers showed a significant increase in portal perfusion pressure after ischemia-reperfusion and a significant decrease in survival rate; fasudil treatment significantly reduced these effects.

Conclusions: Activation of Rho/Rho-kinase signaling in hepatic stellate cells isolated from steatotic livers is associated with an increased susceptibility to ischemia-reperfusion injury. A Rho-kinase inhibitor attenuated the activation of hepatic stellate cells isolated from steatotic livers and improved ischemia-reperfusion injury in steatotic rats.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / analogs & derivatives
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / pharmacology
  • Actin Depolymerizing Factors / metabolism
  • Animals
  • Endothelin-1 / blood
  • Fatty Liver / complications
  • Fatty Liver / drug therapy*
  • Fatty Liver / enzymology*
  • Fatty Liver / pathology
  • Hepatic Stellate Cells / drug effects
  • Hepatic Stellate Cells / enzymology
  • Hepatic Stellate Cells / pathology
  • Liver / drug effects
  • Liver / enzymology*
  • Liver / injuries*
  • Male
  • Myosin Light Chains / metabolism
  • Phosphorylation
  • Protein Kinase Inhibitors / pharmacology
  • Rats
  • Rats, Wistar
  • Reperfusion Injury / enzymology
  • Reperfusion Injury / etiology
  • Reperfusion Injury / prevention & control*
  • rho-Associated Kinases / antagonists & inhibitors*

Substances

  • Actin Depolymerizing Factors
  • Endothelin-1
  • Myosin Light Chains
  • Protein Kinase Inhibitors
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
  • rho-Associated Kinases
  • fasudil